On October 23, 2024, Clene Inc. disclosed the preliminary design of its RESTORE-ALS Phase 3 clinical trial for CNM-Au8 30 mg at the Annual NEALS Meeting. The trial is an international effort aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The details of the presentation were furnished in Exhibit 99.1, attached to the company's Current Report on Form 8-K filed with the SEC. Clene Inc. clarified that the information provided, including the presentation, is not considered 'filed' under the Securities Exchange Act of 1934 and is not subject to its liabilities. Furthermore, the information should not be incorporated by reference into any future filings by the company, except as explicitly stated in such filings.

On October 23, 2024, Clene Inc. disclosed the preliminary design of its RESTORE-ALS Phase 3 clinical trial for CNM-Au8 30 mg at the Annual NEALS Meeting. The trial is an international effort aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The details of the presentation were furnished in Exhibit 99.1, attached to the company's Current Report on Form 8-K filed with the SEC. Clene Inc. clarified that the information provided, including the presentation, is not considered 'filed' under the Securities Exchange Act of 1934 and is not subject to its liabilities. Furthermore, the information should not be incorporated by reference into any future filings by the company, except as explicitly stated in such filings.